Haven Capital Group Inc. Acquires New Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Haven Capital Group Inc. purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 13,704 shares of the company's stock, valued at approximately $5,666,000. IDEXX Laboratories comprises about 5.3% of Haven Capital Group Inc.'s investment portfolio, making the stock its 5th largest position.

Other hedge funds have also added to or reduced their stakes in the company. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories in the third quarter worth $25,000. Rialto Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $30,000. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $31,000. Kestra Investment Management LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $38,000. Finally, Crews Bank & Trust bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $41,000. 87.84% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the company's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company's stock.

Remove Ads

IDEXX Laboratories Stock Up 0.1 %

IDXX traded up $0.37 during midday trading on Friday, reaching $420.99. The company's stock had a trading volume of 706,610 shares, compared to its average volume of 550,872. The firm has a market capitalization of $34.12 billion, a price-to-earnings ratio of 39.46, a PEG ratio of 3.41 and a beta of 1.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $548.88. The stock's 50-day moving average is $437.36 and its 200-day moving average is $445.11.

Analyst Ratings Changes

IDXX has been the subject of several recent analyst reports. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an "outperform" rating and a $500.00 price objective for the company. StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday, March 15th. Morgan Stanley lowered their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Piper Sandler upped their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Finally, Bank of America increased their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.